Nawroth R - Search Results

1

CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.

Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Draeger B, Nawroth R. Pan Q, et al. Among authors: nawroth r. Bladder Cancer. 2017 Apr 27;3(2):79-88. doi: 10.3233/BLC-170105. Bladder Cancer. 2017. PMID: 28516152 Free PMC article. Review.

2

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.

Sathe A, Guerth F, Cronauer MV, Heck MM, Thalgott M, Gschwend JE, Retz M, Nawroth R. Sathe A, et al. Among authors: nawroth r. Br J Cancer. 2014 Nov 25;111(11):2103-13. doi: 10.1038/bjc.2014.534. Epub 2014 Nov 4. Br J Cancer. 2014. PMID: 25349966 Free PMC article.

3

Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012.

Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dräger BJ. Nawroth R, et al. Urol Oncol. 2014 Oct;32(7):1049-50. doi: 10.1016/j.urolonc.2014.02.008. Epub 2014 Oct 29. Urol Oncol. 2014. PMID: 25443142 No abstract available.

4

CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1.

Sathe A, Koshy N, Schmid SC, Thalgott M, Schwarzenböck SM, Krause BJ, Holm PS, Gschwend JE, Retz M, Nawroth R. Sathe A, et al. Among authors: nawroth r. J Urol. 2016 Mar;195(3):771-9. doi: 10.1016/j.juro.2015.08.082. Epub 2015 Aug 28. J Urol. 2016. PMID: 26318986

5

Taking the next step-Advancing bladder cancer management.

Vlahou A, Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Vlahou A, et al. Among authors: nawroth r. Urol Oncol. 2016 Oct;34(10):435-6. doi: 10.1016/j.urolonc.2016.03.004. Urol Oncol. 2016. PMID: 27658683 No abstract available.

6

Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin.

Schmid SC, Sathe A, Guerth F, Seitz AK, Heck MM, Maurer T, Schwarzenböck SM, Krause BJ, Schulz WA, Stoehr R, Gschwend JE, Retz M; German Bladder Cancer Network; Nawroth R. Schmid SC, et al. Among authors: nawroth r. Urol Oncol. 2017 Sep;35(9):544.e1-544.e10. doi: 10.1016/j.urolonc.2017.04.015. Epub 2017 May 10. Urol Oncol. 2017. PMID: 28501564

7

Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma.

Skowron MA, Sathe A, Romano A, Hoffmann MJ, Schulz WA, van Koeveringe GA, Albers P, Nawroth R, Niegisch G. Skowron MA, et al. Among authors: nawroth r. Urol Oncol. 2017 Sep;35(9):544.e11-544.e23. doi: 10.1016/j.urolonc.2017.05.003. Epub 2017 May 25. Urol Oncol. 2017. PMID: 28551413

8

Non-invasive imaging of engineered human tumors in the living chicken embryo.

Jefferies B, Lenze F, Sathe A, Truong N, Anton M, von Eisenhart-Rothe R, Nawroth R, Mayer-Kuckuk P. Jefferies B, et al. Among authors: nawroth r. Sci Rep. 2017 Jul 10;7(1):4991. doi: 10.1038/s41598-017-04572-1. Sci Rep. 2017. PMID: 28694510 Free PMC article.

9

Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.

Sathe A, Nawroth R. Sathe A, et al. Among authors: nawroth r. Methods Mol Biol. 2018;1655:335-350. doi: 10.1007/978-1-4939-7234-0_23. Methods Mol Biol. 2018. PMID: 28889395 Review.

10

Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.

Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R. Sathe A, et al. Among authors: nawroth r. PLoS One. 2018 Jan 22;13(1):e0190854. doi: 10.1371/journal.pone.0190854. eCollection 2018. PLoS One. 2018. PMID: 29357370 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters